Methocarbamol

Muscle Relaxant Centrally Acting Skeletal Muscle Relaxant

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog PO 15-20 mg/kg q8h (every 8 hours) Duration: 5-7 days or as needed
Notes: For acute muscle spasms. May be given with food to reduce GI upset. For IVDD, often used in combination with corticosteroids or NSAIDs.
Dog IV (slow) 44 mg/kg (maximum 330 mg/kg/day) q8h to q12h Duration: 1-2 days, then switch to oral
Notes: Administer slowly (over 5-10 minutes) to avoid hypotension and bradycardia. For severe muscle spasms or tetanus.
Cat PO 20-40 mg/kg q8h to q12h Duration: 5-7 days or as needed
Notes: Use with caution in cats due to increased sensitivity to CNS depression. May cause sedation.
Cat IV (slow) 20-40 mg/kg (maximum 200 mg/kg/day) q8h to q12h Duration: 1-2 days, then switch to oral
Notes: Administer slowly. Monitor for respiratory depression.
Horse PO 20-40 mg/kg q12h Duration: 3-5 days or as needed
Notes: For muscle spasms and myositis. May be used as an adjunct to NSAIDs.
Horse IV (slow) 10-25 mg/kg (maximum 50 mg/kg/day) q12h Duration: 1-2 days, then switch to oral
Notes: Administer slowly over 5-10 minutes. Monitor for ataxia and sedation.
Cattle IV (slow) 10-20 mg/kg q12h Duration: 1-3 days
Notes: For tetanus and muscle spasms. Use with caution in cattle due to potential for bloat and recumbency.
Small Ruminants (Sheep/Goats) IV (slow) 10-20 mg/kg q12h Duration: 1-3 days
Notes: Off-label use. Monitor for sedation and respiratory depression.
Rabbit PO 20-40 mg/kg q8h to q12h Duration: 3-5 days
Notes: Off-label use. Limited safety data; use with caution.

Clinical Indications & Species Uses

General Indications
  • Symptomatic relief of acute musculoskeletal conditions
  • Adjunct in the management of tetanus and strychnine poisoning
Dog (Canine)
  • Relief of acute inflammatory and traumatic muscle spasms
  • Treatment of intervertebral disc disease (IVDD) as an adjunct to anti-inflammatory therapy
  • Management of muscle spasms due to trauma, surgery, or toxicity (e.g., strychnine poisoning)
Cat (Feline)
  • Relief of muscle spasms associated with trauma or inflammation
  • Adjunct therapy for intervertebral disc disease (less common)
  • Management of muscle spasms due to toxicity (e.g., strychnine)
Horse (Equine)
  • Relief of muscle spasms and myositis
  • Adjunct therapy for exertional rhabdomyolysis (tying-up)
  • Management of muscle spasms due to trauma or surgery
Cattle (Bovine)
  • Relief of muscle spasms associated with parturition (dystocia) or trauma
  • Adjunct therapy for tetanus (in combination with other treatments)
Small Ruminants (Sheep / Goat)
  • Relief of muscle spasms associated with trauma or tetanus (off-label use)
Rabbit & Small Mammals
  • Relief of muscle spasms (off-label use)

Pharmacology & Mechanism of Action

Drug Class: Muscle Relaxant | Pharmacological Group: Centrally Acting Skeletal Muscle Relaxant

Mechanism of Action: Methocarbamol is a centrally acting skeletal muscle relaxant. Its exact mechanism is not fully understood, but it is believed to produce its effects by depressing the central nervous system (CNS), particularly at the level of the brainstem and spinal cord. It may inhibit polysynaptic reflexes in the spinal cord and subcortical areas of the brain, leading to muscle relaxation without loss of consciousness. It does not directly affect the neuromuscular junction or the muscle fiber itself.

Pharmacodynamics: Methocarbamol produces skeletal muscle relaxation by depressing the CNS. It has sedative properties and can cause drowsiness. It is effective in reducing muscle spasms and hypertonia associated with acute inflammatory and traumatic conditions. It does not have analgesic properties, but by relieving muscle spasms it can indirectly reduce pain. The onset of action after IV administration is rapid (within minutes), while oral administration may take 30 minutes to 1 hour.

⚑ Pharmacokinetics Summary

Absorption: Methocarbamol is well absorbed after oral administration in most species. In dogs, oral bioavailability is approximately 100% (based on studies). Food may delay absorption but not the extent.
Distribution: Methocarbamol is widely distributed throughout the body, including the CNS. It crosses the blood-brain barrier and placenta. It is distributed into milk in lactating animals. The volume of distribution is approximately 0.8 L/kg in dogs.
Metabolism: Methocarbamol is extensively metabolized in the liver via dealkylation and hydroxylation. The major metabolic pathway involves O-demethylation and glucuronide conjugation. In dogs, the primary metabolite is 3-(o-methoxyphenoxy)-1,2-propanediol (guaifenesin), which is also pharmacologically active.
Excretion: Methocarbamol and its metabolites are excreted primarily in the urine. In dogs, approximately 50-70% of the dose is excreted in urine within 24 hours, mostly as metabolites. A small amount is excreted in feces.
Half-Life: Dog: 1.5-2 hours; Cat: approximately 1-2 hours; Horse: approximately 1.5 hours; Cattle: approximately 1-2 hours (estimated).
Bioavailability: Oral bioavailability is high in dogs (near 100%) and likely similar in other species. In horses, oral bioavailability is approximately 50-60% due to first-pass metabolism.
Protein Binding: Methocarbamol is approximately 46-50% bound to plasma proteins in dogs.

Available Formulations & Strengths

Oral Tablet 500 mg, 750 mg (PO)
Injectable Solution 100 mg/mL (20 mL vial) (IV)

Contraindications & Clinical Warnings

Contraindications:
  • Known hypersensitivity to methocarbamol or any component of the formulation
  • Severe renal impairment (due to propylene glycol content in injectable formulation)
  • Comatose patients or those with severe CNS depression
  • Concurrent use with other CNS depressants (e.g., barbiturates, opioids) without careful monitoring
Warnings & Clinical Precautions:
  • Use with caution in animals with hepatic disease (metabolized in liver)
  • Use with caution in animals with renal disease (excreted in urine; injectable contains propylene glycol)
  • May cause sedation and ataxia; avoid activities requiring coordination
  • In horses, IV administration may cause transient ataxia, weakness, and recumbency; administer slowly
  • In cattle, use with caution due to risk of bloat and regurgitation; keep animal in sternal recumbency if possible
  • Safety in pregnant or lactating animals has not been established; use only when clearly needed
  • Do not administer intra-arterially (risk of thrombosis)
  • Injectable formulation contains propylene glycol; rapid IV administration may cause hypotension and bradycardia

Adverse Effects & Reactions

Common:

  • Sedation
  • Ataxia
  • Weakness
  • Drowsiness
  • Vomiting (oral administration)
  • Hypersalivation (especially in cats)

Serious / Severe:

  • Respiratory depression (especially with high doses or concurrent CNS depressants)
  • Hypotension (with rapid IV administration)
  • Bradycardia (with rapid IV administration)
  • Muscle weakness and recumbency (in horses)
  • Anaphylaxis (rare)

Rare:

  • Hepatotoxicity (reported in dogs with prolonged use)
  • Blood dyscrasias (rare)
  • Seizures (paradoxical, rare)

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
CNS depressants (barbiturates, opioids, phenothiazines, anesthetics) Additive CNS depression, increased sedation and respiratory depression High
Anticholinesterase agents (e.g., neostigmine) May antagonize the effects of anticholinesterase agents; use with caution Moderate
Warfarin and other anticoagulants Methocarbamol may enhance the anticoagulant effect (case reports in humans); monitor coagulation Moderate
Pyridostigmine May reduce the effectiveness of pyridostigmine in myasthenia gravis Moderate

Overdose & Toxicity Management

Signs of Toxicity:

  • Severe CNS depression
  • Coma
  • Respiratory depression
  • Hypotension
  • Bradycardia
  • Ataxia
  • Muscle weakness
  • Seizures (paradoxical)

Emergency Treatment Protocol: Treatment is primarily supportive. Induce emesis (if oral overdose and within 1-2 hours) in conscious animals. Administer activated charcoal to reduce absorption. Provide IV fluids to support blood pressure. Monitor respiratory and cardiac function; provide oxygen and ventilatory support if needed. Use anticonvulsants (e.g., diazepam) for seizures. There is no specific antidote. In severe cases, consider hemodialysis (methocarbamol is dialyzable).

Food Animal Withdrawal Times

πŸ₯© Meat: 7 daysπŸ₯› Milk: 3 days

Withdrawal times are not officially established for methocarbamol in food animals. The values provided are conservative estimates based on pharmacokinetic data and common practice. Always consult local regulations and a veterinarian for specific withdrawal periods.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature (20-25Β°C, excursions permitted to 15-30Β°C).

Handling & Special Conditions: Protect from freezing. Keep container tightly closed. Store injectable solution away from direct heat.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for use in dogs and horses (injectable and oral forms). Not approved for food animals, but extra-label use is permitted under AMDUCA.

Extra-Label (Off-Label) Use: In the USA, methocarbamol is approved for use in dogs and horses. Use in other species (e.g., cats, cattle, small ruminants) is considered extra-label and requires a valid veterinarian-client-patient relationship (VCPR) and compliance with AMDUCA regulations. For food animals, withdrawal times must be extended and residue testing may be required.

Clinical Pearls & Practice Notes

πŸ’‘ Clinical Insights: Methocarbamol is a valuable adjunct in the management of acute muscle spasms and hypertonia. It is particularly useful in dogs with intervertebral disc disease (IVDD) to reduce muscle spasms and facilitate recovery. It is also used in horses for exertional rhabdomyolysis and in cattle for tetanus. The drug is generally well-tolerated, but sedation and ataxia are common. In horses, IV administration should be done slowly to avoid severe ataxia and recumbency. In cats, use lower doses and monitor for excessive sedation. For food animals, be mindful of withdrawal times. Methocarbamol does not have analgesic properties, so concurrent pain management is often necessary. It can be used in combination with NSAIDs or corticosteroids, but caution is advised with concurrent CNS depressants.

References & Literature

  • πŸ“š Plumb's Veterinary Drug Handbook
  • πŸ“š Papich Veterinary Pharmacology and Therapeutics
  • πŸ“š Compendium of Veterinary Products (CVP)